NEXT Austin

Austin, Texas 78758

10 studies enrolling now · 15 studies all time

What they study most

Advanced Hematologic Tumors, Advanced Solid Tumor, Advanced Solid Tumors, Advanced Solid Tumors, Adult, Advanced or Metastatic Solid Tumor, Cancer, Cervical Cancer, Colorectal Cancer, Cutaneous Melanoma, Endometrial Cancer, Esophageal Cancer, Esophageal Squamous Cell Cancer

Studies at this site

• A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer — Recruiting now
• A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors — Recruiting now
• A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors — Recruiting now
• Study of HLD-0915 in Patients With Metastatic Prostate Cancer — Recruiting now
• Study of XB010 in Subjects With Solid Tumors — Recruiting now
• Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment — Recruiting now
• Study of GS-0201 Alone and in Combination in Participants With Advanced Solid Tumors — Recruiting now
• A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-159642 in Participants With Advanced Solid Tumors — Recruiting now
• A Study to Investigate the Safety and Efficacy of KQB168 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies — Recruiting now
• A Study of ADRX-0405 in Subjects With Select Advanced Solid Tumors — Recruiting now
• A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents — Recruiting now
• A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130850 in Participants With Advanced Solid and Hematologic Tumors — Stopped early
• A Study of ES002023 (Anti-CD39 Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors — Completed
• Phase 1 Dose Escalation Study for VIP236 in Patients With Advanced Cancer — Completed
• A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents — Status unconfirmed